Drug Trial Radar · NCT06153329
A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Dec 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Jun 17, 2021
Primary completion
Jun 6, 2022
Study completion Jun 6, 2022
Sponsor
- Lead sponsor
- Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, single-dose, open-label, positive-controlled, randomized, three-cycle, crossover 8-hour euglycemic clamp study to evaluate the PK, PD, safety and tolerability of THDB0206 injection after subcutaneous injection in healthy Chinese subjects. This trial will enroll 39 subjects to receive the investigational medicinal products.
Conditions
- Healthy
Interventions
THDB0206 injectionDrug
0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
Humalog®Drug
0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
BC222insulin lispro injectionDrug
0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCLisp(0-30 min)Time frame: From 0 to 30 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.